Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Izuforant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 20/20 | 0.86 |
| ▸ | HTR3A | P46098 | 2/20 | 0.86 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Izuforant SCHEMBL29906520 | 1.00 | HRH4 (0.86) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14829381 | 0.99 | HRH4 (0.88) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14828833 | 0.97 | HRH4 (0.88) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL30839512 | 0.94 | HRH4 (0.80) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL27075814 | 0.94 | HRH4 (0.98) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL31539860 | 0.94 | HRH4 (0.98) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL30839510 | 0.94 | HRH4 (0.82) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL14828792 | 0.93 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL37560645 | 0.93 | HRH4 (1.00) | HRH4HTR3AHRH3 | |
| Izuforant SCHEMBL27188718 | 0.93 | HRH4 (1.00) | HRH4HTR3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612405-B2 | Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2026-04-28 | — | — | US | claimed |
| US-20240166648-A1 | Novel Crystalline Form Of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-A]pyrazin-4-Yl)-Nmethylazetidin-3-Amine Hydrogen Sulfate Monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2024-05-23 | — | — | US | claimed |
| EP-4313982-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2024-02-07 | — | — | EP | claimed |
| EP-4067357-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2022-10-05 | — | — | EP | claimed |
| US-12612405-B2 | Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12612405-B2 | Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2026-04-28 | — | — | US | disclosed |
| EP-4313982-A4 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2025-04-02 | — | — | EP | disclosed |
| US-20240166648-A1 | Novel Crystalline Form Of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-A]pyrazin-4-Yl)-Nmethylazetidin-3-Amine Hydrogen Sulfate Monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2024-05-23 | — | — | US | disclosed |
| US-20240166648-A1 | Novel Crystalline Form Of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-A]pyrazin-4-Yl)-Nmethylazetidin-3-Amine Hydrogen Sulfate Monohydrate | JW PHARMACEUTICAL CORPORATION (KR) | 2024-05-23 | — | — | US | disclosed |
| EP-4313982-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313982-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| EP-4313982-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208345-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022208345-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-10-06 | — | — | WO | disclosed |
| EP-4067357-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2022-10-05 | — | — | EP | disclosed |
| EP-4067357-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2022-10-05 | — | — | EP | disclosed |
| EP-4067357-A1 | NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3-E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-N-METHYLAZETIDIN-3-AMINE HYDROGEN SULFATE MONOHYDRATE | JW Pharmaceutical Corporation (KR) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612405-B2 | Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate | HRH1, HRH4, HRH2 | HRH4 2/4885HTR3A 50/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.